Determinants of late metastases in renal cell carcinoma
Overall, these findings advocate for recognition of late metastatic RCC because of its distinct biology and improved prognosis.
Authors
- Bradley C. Leibovich (ORCID: https://orcid.org/0000-0003-0043-6659)
- Vanina Toffessi Tcheuyap (ORCID: https://orcid.org/0000-0002-6817-9241)
- David D. Thiel (ORCID: https://orcid.org/0000-0002-5926-3636)
- Jeffrey Miyata (ORCID: https://orcid.org/0000-0001-8278-3026)
- Samuel O. Antwi (ORCID: https://orcid.org/0000-0003-2372-9489)
- Alana Christie (ORCID: https://orcid.org/0000-0002-7034-818X)
- Hua Zhong (ORCID: https://orcid.org/0000-0003-1962-2603)
- Qi Cai (ORCID: https://orcid.org/0000-0002-2562-3955)
- James Brugarolas (ORCID: https://orcid.org/0000-0002-8575-499X)
- Ellen Araj
- Alexander S. Parker (ORCID: https://orcid.org/0000-0001-6820-274X)
- Payal Kapur (ORCID: https://orcid.org/0000-0002-4239-0495)
- Zora Modrušan (ORCID: https://orcid.org/0009-0003-5647-5195)
- John C. Cheville (ORCID: https://orcid.org/0000-0002-8202-6268)
- David Kim (ORCID: https://orcid.org/0000-0001-6896-6950)
- Haitao Xu
- Colleen T. Ball
Institutions
- Mayo Clinic (US)
- Jacksonville College (US)
- WinnMed (US)
- Jacksonville University (US)
- Mayo Clinic in Arizona (US)
- Office of International Affairs (US)
- Mayo Clinic in Florida (US)
- Genomic Health (United States) (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1093/jnci/djaf060
- Citations
- 5
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 7.59